GSK plc (LON:GSK) Receives Average Rating of “Hold” from Analysts

GSK plc (LON:GSK) has earned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is GBX 1,829.17.

GSK has been the subject of several analyst reports. Berenberg Bank upped their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,100 price target on shares of GSK in a report on Wednesday, January 7th. UBS Group restated a “neutral” rating and issued a GBX 1,940 price objective on shares of GSK in a report on Friday. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 7th. Finally, Shore Capital reaffirmed a “buy” rating on shares of GSK in a research note on Thursday, January 8th.

GSK Stock Performance

Shares of GSK stock opened at GBX 1,804.50 on Friday. GSK has a 12-month low of GBX 1,242.50 and a 12-month high of GBX 1,909.73. The company has a 50 day moving average of GBX 1,817.31 and a 200-day moving average of GBX 1,627.41. The firm has a market cap of £72.80 billion, a P/E ratio of 13.57, a PEG ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64.

GSK (LON:GSK) last posted its earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share (EPS) for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Sell-side analysts anticipate that GSK will post 175.980975 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Jonathan Symonds bought 1,650 shares of the business’s stock in a transaction on Monday, December 22nd. The stock was acquired at an average price of GBX 1,810 per share, with a total value of £29,865. Also, insider Wendy Becker purchased 441 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. 0.20% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.